Software helps improve clinical trial performance.
Share:
Press Release Summary:
Designed for pharmaceutical, biotech, CRO, medical technology companies, and academic research institutions, StudyOptimizer v3.5 automates clinical recruitment process with integrated predictive modeling, analytics, simulation, and visualization abilities resulting in clinical trials performance optimization. It delivers recruitment planning to include recruitment rate variables such as seasonality, and facilitates automated data aggregation from disparate financial and clinical systems.
Original Press Release:
DecisionView Launches StudyOptimizer(TM) 3.5 for Improved Clinical Trial Performance
StudyOptimizer 3.5 Enhances Clinical Recruitment Performance & Delivers Measurable Business Results
SAN FRANCISCO, April 30 /- DecisionView Inc., the leading provider of business performance optimization software for the life sciences industry, announced today the immediate availability of StudyOptimizer 3.5 -- the industry's first business performance optimization application for clinical trials.
Designed for pharmaceutical, biotech, CRO, medical technology companies and academic research institutions, StudyOptimizer 3.5 automates the clinical recruitment process with integrated predictive modeling, analytics, simulation and rich visualization capabilities resulting in shorter cycle times, reduced recruitment costs and improved clinical operational efficiencies.
"Delays in recruitment are a leading cause of overall clinical trial delays and escalating clinical trial costs. StudyOptimizer 3.5 provides life science companies with a comprehensive application for improving the mission critical recruitment process and achieving tangible business results," said Steve Andrade, CEO, DecisionView.
The new version delivers dynamic recruitment planning to include recruitment rate variables such as seasonality for developing robust clinical recruitment plans; advanced simulation modeling and predictive analytics that enable clinical study managers to model course corrections and alternative recruitment strategies; and rich interactive visualizations, including performance alerts and dashboards at the study, country and site level. In addition, StudyOptimizer 3.5 further enhances automated data aggregation from disparate financial and clinical systems such as CTMS and EDC, driving improvements in clinical team productivity.
"Today's studies must reach a global patient pool and succeed in meeting their enrollment targets. By enabling consistent planning, dynamic performance forecasts and helpful visuals of enrollment progress, DecisionView's StudyOptimizer can help study management teams succeed in efficient and effective enrollment across multiple countries," said Jane W. Schafer, Executive Director, Global Study Planning & Technical Services, Amgen Inc.
About DecisionView
DecisionView develops innovative software solutions that optimize the business performance of life sciences organizations around the world. By uniquely converging predictive analytics, simulation, visualization and data aggregation capabilities into functionally rich and easy to use applications, the company's solutions deliver proven business value in reducing clinical costs and improving clinical productivity. Granite Ventures, Partech International and Adobe Ventures are primary investors in the company.
Additional information about DecisionView can be found at www.decisionview.com/.
Source: DecisionView Inc.
CONTACT:
Linda Drumright,
COO, DecisionView Inc.,
+1-415-694-6207,
or linda.drumright@decisionviewsoftware.com
Web site: http://www.decisionview.com/
